VII-31 is an activator of the NEDDylation pathway, capable of inducing apoptosis in MCF-7, PC-3, and MGC-803 cells.

PC-3 cells:1.15±0.28μM, MCF-7 cells:0.10±0.006 μM, MGC803 cells:0.09±0.01 μM

Methods: MGC803, MCF-7 and PC-3 cells were treated with VII-31 (0-200 μM, 48 hours), and cell viability was detected by MTT assay.
Results: VII-31 inhibited the cell viability of MGC803, MCF-7 and PC-3 cells, with IC50 values ​​of 0.09±0.01 μM, 0.10±0.006 and 1.15±0.28 μM, respectively. [1]

Methods: VII-31 (10, 50, 150 mg/kg, subcutaneous injection, 28 days) was used to treat MGC803 cancer cells to establish a subcutaneous transplant tumor model of human gastric cancer. The tumor size was measured with a caliper to study its effect on tumors in mice.
Results: Within 28 days after the first treatment, the tumor volume of mice in the VII-31 treatment group was significantly smaller than that in the control group; the tumor weight of the 50 mg/kg VII-31 treatment group was about 36% lower than that in the control group, and the tumor weight of the 100 mg/kg VII-31 and 150 mg/kg VII-31 treatment groups was 42% and 46% lower than that in the control group, respectively. VII-31 was able to inhibit the progression of tumors in mice and had no obvious toxicity to mice. [1]